RxDoctor Payments Data

Rodolfo Penaflor, MD

Internal Medicine · Tucson, AZNPI 1821072018

Payments from drug & device makers

$244in general payments, 2019–2025

Across 10 payments — averaging $24.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$121
  • Pfizer$37
  • Philips North America LLC$30
  • GSK$26
  • Vifor Pharma, Inc.$18
  • Merck$12

What the payments were for

  • Food & beverage$244100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$244 in reported general payments places this provider in the 55th percentile of 2,212 internal medicine providers in Arizona.

See all internal medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$122,779
Medicare patients
418
Services billed
1,157

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban85$95,668
XareltoRivaroxaban34$50,486
JardianceEmpagliflozin29$42,002
OzempicSemaglutide26$39,489
Repatha SureclickEvolocumab13$21,216
Xtampza ErOxycodone Myristate21$20,671
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$19,580
LivaloPitavastatin Calcium22$17,530
OxycontinOxycodone Hcl14$16,006
LinzessLinaclotide13$14,289
Gabapentin269$8,700
SymbicortBudesonide/Formoterol Fumarate31$8,205
Levothyroxine Sodium608$6,818
Duloxetine Hcl185$5,768
Rosuvastatin Calcium484$5,641

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$37$95,66885 claims
Boehringer IngelheimJardiance$121$42,00229 claims
GSKTrelegy Ellipta$26$19,58016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,212 internal medicine providers in Arizona.

Other internal medicine in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →